Dr Calvo talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)
The treatment induced objective responses in 67% of the patients, including 10% of them where all signs of cancer disappeared.
Every patient with SCLC denominated primary chemotherapy-sensitive (their chemotherapy-free interval is more than 90 days) responded to treatment, including 18% of complete responses.
In primary chemotherapy-resistant patients, where cancer was progressing within 90 days or less of previous chemotherapy, a remarkable 30% achieved a response.
Notably, the treatment resulted in durable responses, with an overall progression-free survival of 4.6 months, which was 3.6 months in resistant patients.
The most common adverse drug reaction was reversible myelosuppresion but no cardiotoxicity or drug-related deaths were observed.